Strategic Relevance of Stem Cell Biobanking for Regenerative Medicine

Umbilical cord blood stem cells allow major therapeutic advances in onco-haematology and rare disorders, as well as promising avenues for research in cell therapies and regenerative medicine. This research program analyses the rapid development of cord blood biobanks worldwide. We compare various business models and assess their medical and economic impact on public health from a macro perspective. We specifically analyze the emergence of in vivo and in vitro disruptive technologies in the field of organ regeneration (3-D bio-printers, bio-scaffolds, expansion media, and collection and cryopreservation technologies). We explore the advent of new business models relying on cell induction and reprogramming technologies (IPs). We also anticipate possible applications for pre-clinical phases (target identification, predictive toxicology, high-throughput molecular screening) and clinical applications for cell therapies in oncology and cardio-surgery.